In This Article:
As global markets navigate a complex landscape marked by trade tensions and monetary policy shifts, Asian indices are showing resilience, with Chinese stocks experiencing gains amid expectations of increased stimulus. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that align with intrinsic value assessments and broader economic conditions.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Chenbro Micom (TWSE:8210) | NT$219.00 | NT$435.49 | 49.7% |
| Pegasus (TSE:6262) | ¥463.00 | ¥922.47 | 49.8% |
| Insource (TSE:6200) | ¥856.00 | ¥1679.39 | 49% |
| Tongqinglou Catering (SHSE:605108) | CN¥21.50 | CN¥41.91 | 48.7% |
| Rise Consulting Group (TSE:9168) | ¥930.00 | ¥1832.38 | 49.2% |
| Aozora Bank (TSE:8304) | ¥1866.00 | ¥3691.52 | 49.5% |
| BalnibarbiLtd (TSE:3418) | ¥1150.00 | ¥2263.13 | 49.2% |
| World Fitness Services (TWSE:2762) | NT$79.90 | NT$157.14 | 49.2% |
| Swire Properties (SEHK:1972) | HK$16.20 | HK$32.26 | 49.8% |
| SAMG Entertainment (KOSDAQ:A419530) | ₩35600.00 | ₩70497.19 | 49.5% |
Here we highlight a subset of our preferred stocks from the screener.
Genscript Biotech
Overview: Genscript Biotech Corporation is an investment holding company involved in the manufacture and sale of life science research products and services across the United States, Europe, Mainland China, Asia Pacific, and other international markets with a market cap of approximately HK$23.47 billion.
Operations: The company's revenue is primarily derived from its Life Science Services and Products segment, which generated $454.95 million, followed by Biologics Development Services at $95.02 million and Industrial Synthetic Biology Products contributing $53.69 million.
Estimated Discount To Fair Value: 43.5%
GenScript Biotech is trading at HK$10.84, significantly below its estimated fair value of HK$19.19, suggesting potential undervaluation based on cash flows. The company's net income surged to US$2.96 billion in 2024 from a prior loss, highlighting strong financial recovery. Recent strategic moves include a licensing agreement with the Broad Institute for Prime Editing technology, enhancing its position in gene editing and potentially driving future revenue growth above the Hong Kong market average of 8.1% per year.
Chongqing Baiya Sanitary Products
Overview: Chongqing Baiya Sanitary Products Co., Ltd. operates in the sanitary products industry and has a market cap of CN¥13.16 billion.